Fox Run Management L.L.C. Takes Position in Fresenius Medical Care AG (NYSE:FMS)

Fox Run Management L.L.C. purchased a new position in Fresenius Medical Care AG (NYSE:FMS) during the fourth quarter, HoldingsChannel reports. The firm purchased 18,195 shares of the company’s stock, valued at approximately $412,000.

Other institutional investors also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in shares of Fresenius Medical Care by 16.6% in the fourth quarter. Signaturefd LLC now owns 7,393 shares of the company’s stock worth $167,000 after buying an additional 1,052 shares in the last quarter. Corient Private Wealth LLC lifted its position in Fresenius Medical Care by 3.4% in the 4th quarter. Corient Private Wealth LLC now owns 88,381 shares of the company’s stock valued at $2,001,000 after acquiring an additional 2,918 shares in the last quarter. Natixis Advisors LLC bought a new stake in shares of Fresenius Medical Care in the 4th quarter worth $332,000. HighTower Advisors LLC raised its stake in shares of Fresenius Medical Care by 7.9% in the fourth quarter. HighTower Advisors LLC now owns 17,890 shares of the company’s stock worth $405,000 after purchasing an additional 1,305 shares during the last quarter. Finally, Moran Wealth Management LLC lifted its holdings in shares of Fresenius Medical Care by 9.1% during the fourth quarter. Moran Wealth Management LLC now owns 254,710 shares of the company’s stock valued at $5,767,000 after purchasing an additional 21,334 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $24.45 on Wednesday. The firm’s 50 day moving average price is $23.93 and its 200-day moving average price is $22.45. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $14.35 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a twelve month low of $17.93 and a twelve month high of $25.25.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial increased their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.